Jimvia Dosage/Direction for Use

Administer without regard to meals.
100 mg once daily as monotherapy or as combination therapy with metformin, a sulfonylurea, insulin (with or without metformin), a PPARy agonist (i.e., thiazolidinediones), metformin plus a sulfonylurea, or metformin plus a PPARy agonist.
When SITAGLIPTIN is used in combination with a sulfonylurea or with insulin, a lower dose of sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea or insulin-induced hypoglycemia.
Dosage adjustment: Renal Impairment: Because there is a dosage adjustment based upon renal function, assessment of renal function is recommended prior to initiation of SITAGLIPTIN and periodically thereafter.
For patients with mild renal impairment (estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73 m² to <90 ml/min/1.73 m²), no dosage adjustment for SITAGLIPTIN is required.
For patients with moderate renal impairment (eGFR ≥45 ml/min/1.73 m² to <60 ml/min/1.73 m²), no dosage adjustment for SITAGLIPTIN is required.
For patients with moderate renal impairment (eGFR ≥30 ml/min/1.73 m² to <45 ml/min/1.73 m²), the dose of SITAGLIPTIN is 50 mg once daily.
For patients with severe renal impairment (eGFR ≥15 ml/min/1.73 m² to <30 ml/min/1.73 m²) or with end-stage renal disease (ESRD) (eGFR <15 ml/min/1.73 m²), including those requiring hemodialysis or peritoneal dialysis, the dose of SITAGLIPTIN is 25 mg once daily. SITAGLIPTIN may be administered without regard to the timing of dialysis.
Hepatic Impairment: Mild to moderate impairment (Child-Pugh classes A and B): No dosage adjustment necessary.
Severe impairment (Child-Pugh class C) has not been studied.